Valuation: Polaryx Therapeutics, Inc.

Market Cap 87.23M 78.19M 71.96M 65.14M 122M 8.28B 124M 856M 344M 4.36B 327M 320M 13.74B P/E 2026 *
-8.97x
P/E 2027 * -6.09x
Enterprise Value 87.23M 78.19M 71.96M 65.14M 122M 8.28B 124M 856M 344M 4.36B 327M 320M 13.74B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day-5.91%
1 week-5.41%
Current month-15.46%
1 month-15.46%
3 months-18.60%
6 months-66.67%
1 week 1.75
Extreme 1.75
1.92
1 month 1.75
Extreme 1.75
2.15
Current year 1.75
Extreme 1.75
48.91
1 year 1.75
Extreme 1.75
48.91
3 years 1.75
Extreme 1.75
48.91
5 years 1.75
Extreme 1.75
48.91
10 years 1.75
Extreme 1.75
48.91
Manager TitleAgeSince
Chief Executive Officer 56 01/03/2023
Director of Finance/CFO 60 01/06/2024
Chief Tech/Sci/R&D Officer 56 01/09/2026
Director TitleAgeSince
Chairman 56 01/06/2021
Director/Board Member 60 01/08/2025
Director/Board Member - 29/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
27/5/26 Buy

Chief Executive Officer

88,453 0.1868%
18/2/26 Buy

Chief Financial Officer

2,867 -
29/1/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
-5.91%-5.41% - - 87.23M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.29%+6.24%+47.86%+206.32% 39.44B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -8.21M -7.56M -6.84M -12.8M -870M -13.04M -89.93M -36.14M -458M -34.39M -33.66M -1.44B -16.42M -14.72M -13.55M -12.27M -22.95M -1.56B -23.36M -161M -64.77M -820M -61.64M -60.32M -2.59B
Net Debt - -
Projected Income Statement - Annual - Polaryx Therapeutics, Inc.
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
30/10/26 US$1.750 -5.91% 32,580
29/10/26 US$1.860 -1.59% 15,386
28/10/26 US$1.890 +0.53% 14,704
27/10/26 US$1.880 +3.30% 14,872
26/10/26 US$1.820 -1.62% 27,516
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Polaryx Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.750USD
Average target price
7.500USD
Spread / Average Target
+328.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Polaryx Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLYX Stock